DEME secures sizable contract for Nordseecluster B wind farm in Germany DEME has secured a sizable contract to carry out the transport and installation works for the inter-array cables for the Nordseecluster B offshore wind farm in Germany. The Nordseecluster is a joint offshore wind project of RWE (51%) and Norges Bank Investment Management (49%). Attachment
DEME wint omvangrijk contract voor het Nordseecluster B windpark in Duitsland DEME heeft een omvangrijk contract binnengehaald voor het transport en de installatie van de inter-array kabels voor het offshore windpark Nordseecluster B in Duitsland. De Nordseecluster is een gezamenlijk offshore windproject van RWE (51%) en Norges Bank Investment Management (49%). Bijlage
In this October update of our Dynamic Top Pick List we are removing VGP while adding Shurgard and Wolters Kluwer. Since its recent inclusion in our Dynamic Top Pick List in July-25, VGPs share rose by 10.6%. While we still believe there is significant upside to the share price, we don't see short term catalysts. In fact, the macro picture remains cloudy with the jury still out on the impact of tariffs and the erratic US policy shifts. Also, we are a bit concerned that competition in Western Eur...
Inventiva Appoints Andrew Obenshain as Chief Executive Officer Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (“CEO”) of the Company. Mr. Obenshain will also join the Company’s Board of Directors. He succeeds Frédéric Cren, the Company’s co-founder...
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général Daix (France), New York City (New York, Etats-Unis), le 1er octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui la nomination d’Andrew Obenshain au poste de Directeur Général, à compter du 1er octobre 2025. M. Obenshain rejoindra également le Conseil d’administration de la Socié...
Over the past month, the EPRA BELUX index has underperformed (total return) the EPRA Developed Europe index by 3.2%, the STOXX50 by 5.4%, and the BEL20 by 3.6%. This underperformance relative to the EPRA Developed Europe Index can be attributed to the stronger performance of UK real estate compared to eurodenominated stocks, as UK equities led the recovery following a selloff in August. Additionally, the BELUX region had already posted strong year-to-date performance, which limited further upsid...
VGP Announces Sustainability Milestones With Highest Industrial New Construction Breeam Score Ever Globally Building B in VGP Park Arad, Romania, has been certified with BREEAM Outstanding, obtaining a score of 96.3%: the highest BREEAM International New Construction score awarded for an industrial building in the world everVGP Park Legnano, Italy, obtained the BREEAM outstanding certificate, being the first building across all use categories in Italy to receive thisHalf of VGP’s buildings delivered in the first half of 2025 has been certified BREEAM Outstanding 29 September 2025 – Antwer...
VGP Kondigt Duurzaamheidsprestaties aan met de Hoogste Industrial New Construction BREEAM-Score Ooit Wereldwijd Gebouw B in VGP Park Arad, Roemenië, is gecertificeerd met BREEAM Outstanding en behaalde een score van 96,3%: de hoogste BREEAM International New Construction-score die ooit aan een industrieel gebouw ter wereld is toegekendVGP Park Legnano, Italië, heeft het BREEAM Outstanding-certificaat behaald en is daarmee het eerste gebouw in Italië dat deze certificering heeft gekregen, ongeacht de gebruikscategorieDe helft van de gebouwen die VGP in de eerste helft van 2025 heeft opgeleve...
Inventiva reported 1H25 results which hold no surprises, and confirmed its cash runway guidance to the end of 3Q26 and timeline for the topline readout from the phase 3 (NATiV3) trial of lanifibranor in MASH, which continues to be guided for 2H26. We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the validated MASH commercial opportunity. Given relative un...
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up to €348 million2, following in particular the completion in April 2025 of enrolment of the Phase 3 clinical trial NATiV3 evaluating lanifibranor in patients with MASHCash runway currently planned until the end of the third quarter of 2026Revenues of €4.5 million recorded in the ...
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme1 à 24,6 millions d’euros au 30 juin 2025Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du financement structuré pouvant atteindre 348 millions d’euros2, à la suite en particulier de la finalisation, en avril 2025, du recrutement pour l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor chez des patients atteints de MASHHorizon de trésorerie prévu jusqu’à l...
A director at Montea NV bought 1,000 shares at 66.400EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.